XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Related Party Transactions (Tables)
 9 Months Ended
Sep. 30, 2024
Related Party Transactions [Line Items]  
Schedule of Fair Value of the Options Granted to Each Individual and the Related Expense Remuneration attributed to key management personnel are summarized as follows:
   Three months
ended
September 30,
2024		   Three months
ended
September 30,
2023		   Nine months
ended
September 30,
2024		   Nine months
ended
September 30,
2023		 
Consulting fees  $101,100    51,250    261,933    153,750 
Salaries   67,353    159,874    445,009    476,126 
Share-based compensation   30,764    124,994    (1,819)   247,348 
   $199,217    336,118    705,123    877,224 
Related Party [Member]  
Related Party Transactions [Line Items]  
Schedule of Fair Value of the Options Granted to Each Individual and the Related Expense Details of the fair value granted to each related party in the current and prior periods, and the related expense recorded for the nine months ended September 30, 2024, and 2023 is as follow:
   Nine Months
Ended
September 30,
2024		   Nine Months
Ended
September 30,
2023		   Fair value of
stock options
granted		 
Braeden Lichti, Chairman  $1,894   $5,398   $50,995 
Graydon Bensler, CEO, CFO and Director   1,897    5,398    50,995 
Jordan Plews, Director and CEO of Skincare and BioSciences   1,897    5,398    50,995 
Tim Sayed, Former Chief Medical Officer and Former Director1   (4,291)   5,398    50,995 
Jeffrey Parry, Director   18,564    21,177    107,669 
Crystal Muilenburg, Former Director1   (41,668)   46,725    210,245 
Julie Daley, Director   69,111    56,022    210,245 
George Kovalyov, Director   18,144    
-
    52,845 
Brenda Buechler, Former Chief Marketing Officer1   (36,918)   
-
    143,671 
Christoph Kraneiss, Former Chief Commercial Officer1   (30,449)   
-
    121,243 
   $(1,819)  $145,516   $1,049,898 
1354,990 options of related parties were forfeited in the nine months ended September 30, 2024.